RecruitingPhase 2NCT06843590
A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic Hypersomnia
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance-3)
Sponsor
Alkermes, Inc.
Enrollment
96 participants
Start Date
May 22, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to measure the safety and decrease in daytime sleepiness in subjects with Idiopathic Hypersomnia when taking ALKS 2680 tablets compared with placebo tablets
Eligibility
Min Age: 18 YearsMax Age: 70 Years
Inclusion Criteria2
- Is willing and able, in the opinion of the Investigator, to understand and comply with protocol requirements, including: lifestyle considerations and restrictions, adherence to contraception guidance, adherence to actigraphy and diary requirements, if receiving treatment for OSA, adherence to primary OSA therapy over the 30 days prior to Visit 1, and throughout the study, including during overnight visits.
- Meets the diagnostic criteria of Idiopathic Hypersomnia according to ICSD-3-TR guidelines, confirmed by the diagnostic evaluations (PSG/MSLT/actigraphy) within the previous 10 years
Exclusion Criteria4
- Has another comorbid sleep disorder or condition that may influence the sleep-wake cycle
- Has a history or presence at Visit 1 of other clinically significant (treated or untreated) illness, disease, abnormality, or surgical procedure that, in the opinion of the Investigator, might compromise subject safety, interfere with any study assessment, or affect the subject's ability to complete the study
- Is currently enrolled in another clinical study or used any investigational drug or device within 30 days prior to Visit 1
- Is currently pregnant, breastfeeding, or is planning to become pregnant during the study
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGALKS 2680
Oral tablet containing ALKS 2680 for once daily administration
DRUGPlacebo
Oral placebo tablet for once daily administration
Locations(48)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06843590
Related Trials
A Phase 3 Efficacy and Safety Study of HBS-301 in Participants With Idiopathic Hypersomnia (IH)
NCT0750009012 locations
A Study of TAK-360 in Adults With Idiopathic Hypersomnia
NCT0681207829 locations
A Long-term Extension Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia
NCT0709667414 locations
A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia
NCT0676768346 locations
A Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia
NCT0675266829 locations